Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Update

Benitec Biopharma Inc. (NASDAQ:BNTC) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totalling 9,500 shares, a decrease of 25.8% from the May 31st total of 12,800 shares. Based on an average daily volume of 96,100 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.4% of the company’s stock are short sold.

Hedge Funds Weigh In On Benitec Biopharma

An institutional investor recently bought a new position in Benitec Biopharma stock. Adage Capital Partners GP L.L.C. purchased a new position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 189,188 shares of the biotechnology company’s stock, valued at approximately $572,000. Adage Capital Partners GP L.L.C. owned approximately 7.42% of Benitec Biopharma as of its most recent SEC filing. Institutional investors own 52.19% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Piper Sandler assumed coverage on Benitec Biopharma in a research note on Thursday, June 13th. They set an “overweight” rating and a $30.00 target price for the company. JMP Securities increased their target price on Benitec Biopharma from $10.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Monday, April 22nd.

Benitec Biopharma Price Performance

NASDAQ BNTC traded down $0.06 during trading hours on Friday, reaching $6.99. 14,534 shares of the company’s stock were exchanged, compared to its average volume of 42,840. The company’s 50-day moving average is $7.93 and its two-hundred day moving average is $5.39. Benitec Biopharma has a one year low of $1.86 and a one year high of $10.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.18 and a quick ratio of 4.18.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($1.64) earnings per share for the quarter. Equities research analysts forecast that Benitec Biopharma will post -7.67 EPS for the current fiscal year.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.